Impella 2.5® Device Is Associated with Improved Survival in AMICS

Slides:

Advertisements

Similar presentations

The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.

Advertisements

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.

The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Amit P. Amin 2,

ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.

Types of Hemodynamic Support in the Cath Lab.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.

Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.

CRT 2015 Unmet Needs in STEMI Interventions

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI

Improving Outcomes in Cardiogenic Shock

Impact of Percutaneous Coronary Angioplasty and Extra-Corporal Life Support on Survival of Patients with Out of Hospital Cardiac Arrest. Morgan Benais,

The Association between Prehospital Time Intervals and ST-Elevation Myocardial Infarction System Performance.

Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

Mortality Related to Periprocedural MI in CTO-PCI

Circ Cardiovasc Interv

Fractional Flow Reserve Workshop

Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Andrew McNeice1,2, Imad J. Nadra1,2, Simon D

Presented by Dr. Leif Thuesen

Nat. Rev. Cardiol. doi: /nrcardio

Baseline characteristics of patients

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

European Heart Association Journal 2007 April

Nat. Rev. Cardiol. doi: /nrcardio

Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study.

Fewer PCIs After Public Reporting Changes in NY

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Giuseppe Biondi Zoccai, MD

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Figure 4 Observational studies on multiple treatment strategies

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

National Trends in the Incidence, Management, and Outcomes of Heart Failure Complications in Patients Hospitalized for ST-Segment Elevation Myocardial.

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Nat. Rev. Cardiol. doi: /nrcardio

Maintenance of Long-Term Clinical Benefit with

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Flow Diagram of the Trial Selection Process

Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock

(A) Meta-analysis of repeat revascularisation in randomised trials.

Collet JP, et al. Lancet 2009;373:309-17

European Heart Journal Advance Access

ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Leslee J. Shaw et al. JIMG 2010;3:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Baseline characteristics of study population

Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE-Retrospective AMI Study Yan Gao, Frederick.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Impella 2.5® Device Is Associated with Improved Survival in AMICS In the setting of acute myocardial infarction (AMI) cardiogenic shock (CS), Impella prior to percutaneous coronary intervention (PCI) has been associated with a survival benefit. To assess outcomes of patients supported with Impella 2.5 prior to and after PCI on unprotected left main coronary artery (ULMCA) culprit lesion in AMICS. This was a retrospective analysis of 36 consecutive patients in the cVAD Registry supported with Impella 2.5 for AMICS who underwent PCI on ULMCA culprit lesion. Baseline characteristics were comparable between the pre- PCI group (n=20) and post-PCI group (n=16). Non-ST segment elevation myocardial infarction and greater coronary disease burden were more frequent in the pre-PCI group, but this group had significantly better survival to discharge (55.0% vs 18.8%). Kaplan Meier 30-day survival analysis showed poor survival in post-PCI group (48.1% vs 12.5%). Impella 2.5 support before PCI on an ULMCA culprit lesion correlates with survival benefit in patients supported for AMICS. Survival rates represent Kaplan-Meier estimates. Kaplan-Meier analysis of survival through 30 days on the entire cohort (n=36) comparing the Pre-PCI group (n=20) and the Post-PCI group (n=16). Kaplan-Meier analysis of survival through 30 days on patients who did not present with anoxic brain injury prior to Impella 2.5 support (n=25) comparing the Pre-PCI group (n=13) and the Post-PCI group (n=12). IM2-050-17 Meraj PM et al. J Interv Cardiol. 2017.